TNGX
TNGX
NASDAQ · Biotechnology

Tango Therapeutics Inc

$21.56
+0.69 (+3.31%)
As of Nov 7, 1:46 AM ET ·
Financial Highlights (FY 2026)
Revenue
90.21M
Net Income
-146,920,127
Gross Margin
—
Profit Margin
-162.9%
Rev Growth
+35.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 30.1% 30.1%
Operating Margin -178.4% -160.6% -20.8% -21.5%
Profit Margin -162.9% -154.7% -27.2% -24.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 90.21M 66.38M 421.41M 456.66M
Gross Profit — — 127.00M 137.62M
Operating Income -160,922,440 -106,578,994 -87,784,070 -98,156,679
Net Income -146,920,127 -97,305,257 -114,600,480 -110,156,724
Gross Margin — — 30.1% 30.1%
Operating Margin -178.4% -160.6% -20.8% -21.5%
Profit Margin -162.9% -154.7% -27.2% -24.1%
Rev Growth +35.9% +35.9% +7.1% +20.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 721.39M 673.97M
Total Equity — — 1.19B 1.15B
D/E Ratio — — 0.61 0.59
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -157,637,602 -110,203,636 -127,773,532 -138,708,079
Free Cash Flow — — -89,915,808 -70,983,895